Literature DB >> 9674493

Intrapulmonary shunting in primary pulmonary hypertension: an observation in two patients treated with epoprostenol sodium.

P F Castro1, R C Bourge, D C McGiffin, R L Benza, P Fan, N B Pinkard, M D McGoon.   

Abstract

Continuous intravenous infusion of epoprostenol sodium in selected patients with primary pulmonary hypertension improves symptoms and survival. This report describes two patients with primary pulmonary hypertension treated with epoprostenol in whom intrapulmonary shunting and severe hypoxemia occurred. Intrapulmonary shunting was confirmed by contrast echocardiography showing delayed appearance of bubbles in the left cardiac chambers after peripheral venous injection of agitated saline solution.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9674493     DOI: 10.1378/chest.114.1.334

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  2 in total

Review 1.  Pulmonary hypertension caused by sarcoidosis.

Authors:  Enrique Diaz-Guzman; Carol Farver; Joseph Parambil; Daniel A Culver
Journal:  Clin Chest Med       Date:  2008-09       Impact factor: 2.878

Review 2.  Sildenafil in the treatment of pulmonary hypertension.

Authors:  Christopher F Barnett; Roberto F Machado
Journal:  Vasc Health Risk Manag       Date:  2006
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.